King Tigan Suppository sNDA Pushed To 2004 Under Revised FDA Agreement
Executive Summary
King has an additional two years to submit an sNDA for Tigan suppositories under an amended agreement with FDA requiring submission by December 2004
You may also be interested in...
No Rest For Sonata: King To Develop XR Version After Acquisition From Elan
King plans to develop an extended-release version of Sonata following an $850 mil. acquisition of Elan's primary care business
No Rest For Sonata: King To Develop XR Version After Acquisition From Elan
King plans to develop an extended-release version of Sonata following an $850 mil. acquisition of Elan's primary care business
Synthroid Sales Expected To Grow 12% For Year Following NDA Approval
Abbott expects Synthroid growth of approximately 12% in 2002 following approval of the synthetic thyroid hormone replacement therapy's NDA